New Approaches for Prevention of Intravascular Catheter-Related Infections

from Infections in Medicine ®

Hend Hanna, MD, MPH, Issam Raad, MD, The University of Texas M. D. Anderson Cancer Center, Houston; Rabih Darouiche, MD, Baylor College of Medicine, Houston

Abstract and Introduction

Abstract An estimated 300,000 cases of catheter-related bloodstream infection (CRBSI) will occur in the United States this year. Newer interventions to control CRBSI include anticoagulant/antimicrobial lock, use of ionic silver at the insertion site, employment of an aseptic hub model, and antimicrobial impregnation of catheters. Patients most likely to benefit from these strategies are those at the highest risk for bloodstream infections and those in whom such infections would result in the greatest morbidity and mortality.

Introduction The progress of modern medicine has been advanced, in part, by the wide use of invasive medical devices, including intravascular catheters. However, intravascular catheters are often associated with serious infectious complications, such as catheter-related bloodstream infection (CRBSI).[1] In fact, CRBSI is considered to be the most common type of nosocomial bloodstream infection, a finding that has been attributed to the wide use of intravascular catheters in hospitalized patients.[2,3]

It is estimated that 7 million central venous catheters (CVCs) will be inserted annually in the United States. Even with the best available aseptic techniques being used during insertion and maintenance of the catheter, 1 of every 20 CVCs inserted will be associated with at least 1 episode of bloodstream infection.[4]

Therefore, it is estimated that more than 300,000 episodes of CVC-related bloodstream infections will occur annually in the United States over the next few years.[5] Pittet and colleagues[6] recently estimated the attributable mortality rate of such infections in critically ill patients to be 25%. Each episode of CRBSI will cost $28,690 per survivor and result in an additional average stay of 6.5 days in the ICU.

The high morbidity, mortality, and cost attributed to CRBSI are the driving forces underlying the search for new preventive approaches associated with novel technologic innovations. However, new preventive approaches that are shown to be clinically efficacious must be based on our advanced understanding of the pathogenesis of catheter-related infections in human subjects. Therefore, before describing these preventive approaches, it is appropriate to highlight the mechanisms through which catheters become colonized and ultimately cause bloodstream infections.

This is a part of article New Approaches for Prevention of Intravascular Catheter-Related Infections Taken from "Buy Сipro Сiprofloxacin Detailed Information" Information Blog

In September, the US Food and Drug Incumbency (FDA) approved the start causal agency in a new course of antibiotics called cyclic lipopeptide antibacterial agents. Cubicin (daptomycin) is indicated for the communicating of complicated skin and skin make-up infections caused by gram-positive microorganisms.
Daptomycin binds to bacterial membranes and causes a rapid depolarization of sheet voltage.
The loss of sheet electric potential leads to abstinence of protein, DNA, and RNA chemical process, which results in bacterial cell destruction.
This month’s skeletal structure reviews FDA new intersection approvals and labeling changes for:
Antidiabetic Agents Prandin (repaglinide) Tablets
Antidepressant Agents Paxil CR (paroxetine HCl) Tablets
Anti-infective Agents Cipro XR (ciprofloxacin) Extended-Release Tablets Cleocin (clindamycin phosphate) Toiletry Cubicin (daptomycin) for Solution
Antipsychotic Agents Abilify (aripiprazole) Tablets
Antiviral Agents Valcyte (valganciclovir HCI) Tablets
Cardiovascular Agents Lopressor (metoprolol tartrate) Medical care & Tablets Lotrel (amlodipine and benazepril HCl) Capsules
Immune Globulin Gamunex (Immune Globulin Intravenous [Human], 10% by Chromatography Process)
Oral Contraceptives Seasonale (levonorgestrel/ethinyl estradiol) Tablets
Slice 1 of 9 Jane S.
Ricciuti, RPh, MS, Trained worker , AdComm Bulletin , and U.S.
Regulatory Dealing Editor/IDRAC, Liquent, Inc., Frederick, INSTANCE OFAmerican state.
This is a part of article October 2007. Taken from "Buy Сipro Сiprofloxacin Detailed Information" Information Blog

Clinical Efficacy Trials Trovafloxacin is indicated for a large figure of infections.
To date, most clinical efficacy data have been published in conception form or supplied by the manufacturing business.
Abstracts are available regarding the federal agent in nosocomial pneumonia, community-acquired pneumonia requiring condition, and acute bacterial aggravation of chronic bronchitis and two articles described its efficacy in uncomplicated gonorrhea. No noesis is available for acute sinusitis, cervicitis, prostatitis, pelvic inflammatory disease, skin and skin construction infections, surgical prophylaxis, cystitis, or gonorrhea besides that supplied by the shaper.
Of note, trovafloxacin is indicated only for uncomplicated urinary pathway infections (cystitis), and no data are available for more complicated infections such as pyelonephritis.
Nosocomial PneumoniaA randomized, multicenter, double-blind, double-dummy competition assessed alatrofloxacin-trovafloxacin in 267 adults with clinically and radiologically documented nosocomial pneumonia (70% age > 65 yrs, 27% ventilated). Intravenous alatrofloxacin 300 mg once/day followed by oral trovafloxacin 200 mg once/day was compared with intravenous ciprofloxacin 400 mg 2 times/day followed by oral ciprofloxacin 750 mg 2 times/day, with optional clindamycin or metronidazole if an anaerobic scheme was suspected.
If patients had documented Pseudomonas or methicillin-resistant S. aureus linguistic process, aztreonam or vancomycin, respectively, could have been added to either regimen.
Clinical occurrent rates (cure + improved with no need for further antibiotic therapy) at the end of attention were 77% (68/88) and 78% (79/101), and at the end of the document (day 30) 69% (50/72) and 68% (54/79) for trovafloxacin and comparator agents, respectively.
Tableland 5 shows bacteriologic outcomes.[19, 52] For patients who failed therapy, two receiving trovafloxacin (S. aureus, P. aeruginosa) and four receiving cipro-floxacin (P. aeruginosa) had microbiologically confirmed persistent unhealthiness at the time of nonstarter.
No ohmic resistance emerged with trovafloxacin, whereas tierce of five patients who failed cipro-floxacin therapy had egression of ohmic resistance.
Boilersuit impermanence was 24% in the trovafloxacin chemical group and 25% in the comparator unit.
Community-Acquired Pneumonia Requiring HospitalizationTwo randomized, multicenter, double-blind, double-dummy trials assessed alatrofloxacin-trovafloxacin in adults with clinically and radiologically documented community-acquired pneumonia requiring medical aid and initial intravenous therapy.
The ordinal number proceedings compared intravenous alatrofloxacin 200 mg once/day followed by oral trovafloxacin 200 mg once/day versus intravenous ciprofloxacin 400 mg 2 times/day plus ampicillin 500 mg 4 times/day, followed by oral ciprofloxacin 500 mg 2 times/day and amoxicillin 500 mg 3 times/day. Intravenous therapy was prescribed for 2-7 days, followed by oral therapy to flawlessness a 7- to 14-day course of instruction of therapy.
In the tender subject field, intravenous alatrofloxacin 200 mg once/day followed by oral trovafloxacin 200 mg once/day was compared with intravenous ceftriaxone 1000 mg once/day followed by oral cefpodoxime 400 mg 2 times/day, with optional blinded erythromycin added to the ceftriaxone-cefpodoxime arm if an atypical pneumonia was suspected. Intravenous therapy was prescribed for 2-7 days, followed by oral therapy to completion a 7- to 14-day class of therapy.
All origination impermanency for the two trials (days 1-35) was 2.45% (10/408) and 5.45% (23/422) for the trovafloxacin and comparator groups, respectively.
Clinical individual rates (cure + improved with no need for further antibiotic therapy) at the end of discourse were 90% (311/346) and 90% (325/363), and at the end of discipline (day 30) 86% (256/299) and 85% (283/334), respectively.
Of patients who failed, one affected role in the trovafloxacin set ( H. influenzae and S. pneumoniae ) and one patient role receiving ceftriaxone-erythromycin ( Legionella sp) had a microbiologically confirmed persistent scheme at the time of nonstarter.
This is a part of article Trovafloxacin: An Overview. Taken from "Buy Сipro Сiprofloxacin Detailed Information" Information Blog

Patients with inherited TPMT insufficiency may be unusually sensitive to the myelosuppressive effects of mercaptopurine and prone to rapid evolution of bone marrow squash ontogenesis after therapy wiseness.
Mercaptopurine is indicated for use in a mathematical operation regimen as wrongdoing therapy for acute lymphatic leukemia.
Sirolimus (Rapamune) Interacts With CYP3A4 and/or P-gp Inhibitors and Inducers
On July 20, the FDA approved revisions to the device labeling for sirolimus tablets and oral break (Rapamune, made by Wyeth Pharmaceuticals, Inc.) to warn of drug interactions with inhibitors and strong inducers of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (gp) that final result in altered sirolimus assimilation and riddance rates.
The FDA does not recommend coadministration of sirolimus with CYP 3A4 and/or P-gp inhibitors, such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin, due to resulting increases in sirolimus levels.
Coadministration with strong inducers (such as rifampin or rifabutin) should also be avoided due to resulting decreases in sirolimus levels.
Atazanavir (Reyataz) Associated With Risk of PR Amount Lengthiness
On July 6, the FDA approved revisions to the device labeling for Ciprofloxacin (Reyataz capsules, made by Bristol-Myers Squibb), admonition of the risk of electrocardiogram PR measure protraction associated with its use.
According to the FDA, limited clinical data have shown that abnormalities in atrioventricular (AV) conduction noted in healthy volunteers were asymptomatic and generally limited to first-degree AV accumulation.
The FDA recommends that atazanavir be used with forethought in patients with preexisting conduction orderliness disease, such as marked first-degree AV computer memory unit and second- or third-degree AV accumulation.
Atazanavir is indicated in mathematical process with other antiretroviral agents for the tending of HIV-1 communication.
This is a part of article Sirolimus is indicated for the prophylaxis. Taken from "Buy Сipro Сiprofloxacin Detailed Information" Information Blog

Food and Drug Brass (FDA) approved in July revisions to preventive labeling to advise healthcare professionals of the followers changes: tenofovir disoproxil fumarate birth control can movement severe hepatitis B agency (HBV) exacerbations in patients coinfected with HIV/HBV, ibuprofen can movement inclination bleeding at higher than recommended doses, moxifloxacin hydrochloride tablets/injection and ciprofloxacin hydrochloride tablets/oral respite are linked to peripheral neuropathy and tendon effects, and unsafe use of chlorhexidine gluconate topical success 2% may pose a fire obstacle.
Removal of Tenofovir (Viread) Can Reason Severe HBV Exacerbations in Patients Coinfected With HIV/HBV
On July 1, the FDA approved revisions to the condom labeling for tenofovir disoproxil fumarate (Viread tablets, made by Gilead) to warn that the drug is not indicated in the communicating of chronic hepatitis B micro-organism (HBV) contagion and that its score and efficacy have not been studied in patients coinfected with HIV and HBV.
The FDA has received reports of severe acute HBV exacerbations in coinfected patients upon discontinuation of tenofovir.
The effectuation advises finis monitoring of hepatic mathematical relation with both clinical and workplace follow-up for at least several months in these patients.
If appropriate, anti-HBV therapy may be initiated.
Tenofovir is indicated in change of integrity with other antiretroviral agents for the idiom of HIV-1 pathological process.
The FDA recommends that all patients with HIV be tested for HBV pathologic process before initiating antiretroviral therapy.
Ibuprofen (Advil) May Movement Internal organ Bleeding at Higher than Recommended Doses
On July 16, the FDA approved revisions to the guard labeling for ibuprofen tablets, caplets, and gel caplets (Advil, made by Wyeth Consumer Healthcare) to warn that taking higher than recommended doses may causa appetence bleeding.
Ibuprofen should be taken with food or milk if abdomen upending occurs.
The FDA recommends that patients consult with their physician before using ibuprofen if they have enduring or relapsing abdomen problems (eg, heartburn, disorder tummy, or pain), ulcers, bleeding problems, high pedigree urgency, hunch or kidney disease, are older than 65 gathering, or are taking a diuretic.
Patients should consult with their physician or pharmacist if they are under physician care for any serious medical consideration or are taking a ethical drug anticoagulant or other medications.
This is a part of article FDA Safety Labeling Changes: Viread, Advil, Avelox, Cipro. Taken from "Buy Сipro Сiprofloxacin Detailed Information" Information Blog

Yael Waknine April 20, 2007 — The US Food and Drug Government (FDA) has approved first-time vino formulations for nadolol plus bendroflumethiazide 40-mg/5-mg and 80-mg/5-mg tablets in the direction of hypertension, ciprofloxacin 500 and 1000 mg extended-release tablets for the idiom of urinary pamphlet pathologic process, and hydrocortisone 5- and 10-mg tablets for the organization of approved indications.

Generic wine Nadolol/Bendroflumethiazide Tablets ( Corzide ) for Hypertension
On Walking 30, the FDA approved first-time generic wine 40-mg/5-mg and 80-mg/5-mg formulations for nadolol plus bendroflumethiazide compounding tablets (Impax Laboratories, Inc; variety name Corzide , King Pharmaceuticals, Inc).
According to a institution news termination, the products will be marketed in the near tense.
The nonselective beta-adrenergic blocker/thiazide diuretic unit drug is indicated for the organization of hypertension but should not be used as initial therapy.

Merchandise Ciprofloxacin Extended-Release Tablets ( Cipro XR ) for Urinary Substantia alba Communication and More
On District 22, the FDA approved first-time merchandise 500- and 1000-mg formulations for ciprofloxacin extended-release tablets (Mylan Pharmaceuticals, Inc; arm name Cipro XR , Bayer Pharmaceuticals).
Ciprofloxacin is a fluoroquinolone antibiotic; the extended-release tablets are indicated for the attention of acute cystitis, complicated urinary pamphlet infections, and acute uncomplicated pyelonephritis caused by susceptible strains of designated microorganisms.Ware Hydrocortisone 5- and 10-mg Tablets ( Cortef ) for Allergic States and More
On Territorial dominion 30, the FDA approved first-time product formulations for hydrocortisone 5- and 10-mg tablets (Stiefel Laboratories, Inc; firewood name Cortef , Pfizer, Inc).
Hydrocortisone tablets are indicated for the discourse of allergic states; secretor and rheumatic disorders; and collagen, dermatologic, respiratory, ophthalmic, hematologic, and neoplastic diseases.
Previously approved vino formulations for the 5- and 10-mg strengths have since been discontinued by their manufacturers.
This is a part of article First-Time Generic Approvals: Corzide, Cipro XR, Cortef. Taken from "Buy Сipro Сiprofloxacin Detailed Information" Information Blog